A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * 1\) Stage IV or recurrent non-Small cell lung cancer * 2\) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * 3\) Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization Exclusion Criteria: * 1\) Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy * 2\) Active, known or suspected autoimmune disease or HIV infection * 3\) Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors) * 4\) Untreated Central Nervous System metastases Other protocol defined inclusion/exclusion criteria could apply